The ROE as of November 2024 (TTM) for Kymera Therapeutics, Inc. (KYMR) is -24.96%

According to Kymera Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -24.96%. This represents a change of 322.95% compared to the average of -5.90% of the last 4 quarters.

Kymera Therapeutics, Inc. (KYMR) Historical ROE (quarterly & annually)

How has KYMR ROE performed in the past?

The mean historical ROE of Kymera Therapeutics, Inc. over the last ten years is 2.14%. The current -24.96% ROE has changed -1265.39% with respect to the historical average. Over the past ten years (40 quarters), KYMR's ROE was at its highest in in the December 2019 quarter at 15.47%. The ROE was at its lowest in in the June 2020 quarter at -13.45%.

Kymera Therapeutics, Inc. (KYMR) ROE by Quarter and Year

Discovering the peaks and valleys of Kymera Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kymera Therapeutics, Inc. (KYMR) Average ROE

How has KYMR ROE performed in the past?

The current ROE of Kymera Therapeutics, Inc. (KYMR) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Kymera Therapeutics, Inc. (KYMR) ROE vs. Peers

How is KYMR’s ROE compared to its peers?

Kymera Therapeutics, Inc.’s ROE is less than Foghorn Therapeutics Inc. (167.93%), greater than Shattuck Labs, Inc. (-61.92%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Nurix Therapeutics, Inc. (-63.39%), greater than Revolution Medicines, Inc. (-33.67%), greater than C4 Therapeutics, Inc. (-42.45%), less than Agios Pharmaceuticals, Inc. (70.20%), greater than Century Therapeutics, Inc. (-66.58%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Prelude Therapeutics Incorporated (-66.88%),

Build a custom stock screener for Kymera Therapeutics, Inc. (KYMR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kymera Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kymera Therapeutics, Inc. (KYMR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kymera Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.